Early Intervention with Low-Dose Sclerostin Antibody Therapy can Reduce Osteocyte-mediated Secondary Mineralization after initial bone loss in Ovariectomised Rats.

A preprint abstract from biorxiv.org discusses the potential benefits of using low-dose sclerostin antibody therapy in the early stages of estrogen deficiency to mitigate bone loss and prevent osteocyte-driven secondary mineralization. The study was conducted on female rats that underwent ovariectomy as a model of postmenopausal osteoporosis. The results suggest that early intervention with intermittent low-dose sclerostin antibody therapy can promote surface bone formation and reduce osteocyte-mediated secondary mineralization after initial bone loss. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)